246 related articles for article (PubMed ID: 24645664)
41. Genetic and phenotypic profile of Fabry disease in the population of Vale do Paraiba and Eastern São Paulo.
Paz OTD; Lacerda RCT; de Andrade LGM
J Bras Nefrol; 2023; 45(4):424-439. PubMed ID: 36745055
[TBL] [Abstract][Full Text] [Related]
42. Rapid Clathrin-Mediated Uptake of Recombinant α-Gal-A to Lysosome Activates Autophagy.
Ivanova MM; Dao J; Kasaci N; Adewale B; Fikry J; Goker-Alpan O
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486191
[TBL] [Abstract][Full Text] [Related]
43. Infertility in Fabry's Disease: role of hypoxia and inflammation in determining testicular damage.
Sansone L; Barreca F; Belli M; Aventaggiato M; Russo A; Perrone GA; Russo MA; Tafani M; Frustaci A
Front Endocrinol (Lausanne); 2024; 15():1340188. PubMed ID: 38455658
[TBL] [Abstract][Full Text] [Related]
44. Neuropathic pain in a Fabry disease rat model.
Miller JJ; Aoki K; Moehring F; Murphy CA; O'Hara CL; Tiemeyer M; Stucky CL; Dahms NM
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563343
[TBL] [Abstract][Full Text] [Related]
45. Asn215Ser, Ala143Thr, and Arg112Cys variants in α-galactosidase A protein confer stability loss in Fabry's disease.
Sudhan M; Janakiraman V; Patil R; Oyouni AAA; Hasan Mufti A; Ahmed SSSJ
J Biomol Struct Dyn; 2023 Nov; 41(19):9840-9849. PubMed ID: 36420638
[No Abstract] [Full Text] [Related]
46. Quality of life in patients with Fabry disease: a systematic review of the literature.
Arends M; Hollak CE; Biegstraaten M
Orphanet J Rare Dis; 2015 Jun; 10():77. PubMed ID: 26076709
[TBL] [Abstract][Full Text] [Related]
47. Diet and Physical Activity in Fabry Disease: A Narrative Review.
Muscogiuri G; De Marco O; Di Lorenzo T; Amicone M; Capuano I; Riccio E; Iaccarino G; Bianco A; Di Risi T; Pisani A
Nutrients; 2024 Apr; 16(7):. PubMed ID: 38613094
[TBL] [Abstract][Full Text] [Related]
48. Interaction of Fabry Disease and Diabetes Mellitus: Suboptimal Recruitment of Kidney Protective Factors.
Sanchez-Niño MD; Ceballos MI; Carriazo S; Pintor-Chocano A; Sanz AB; Saleem MA; Ortiz A
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958836
[TBL] [Abstract][Full Text] [Related]
49. Morbus Fabry and Parkinson's Disease-More Evidence for a Possible Genetic Link.
Müller S; Kassubek J; Hold ST; Kasper DC; Mayer B; Müller K; Freischmidt A; Siebert R; Braak H; Ludolph AC; Del Tredici K
Mov Disord; 2024 Feb; 39(2):449-451. PubMed ID: 38226450
[No Abstract] [Full Text] [Related]
50. Respiratory impairments in patients suffering from Fabry disease - A cross-sectional study.
Ahmed H; Backer V; Effraimidis G; Rasmussen ÅK; Kistorp CM; Feldt-Rasmussen U
Chron Respir Dis; 2024; 21():14799731231221821. PubMed ID: 38334083
[TBL] [Abstract][Full Text] [Related]
51. Cochleovestibular Signs As the First Manifestation of Fabry Disease: A Case Report and Literature Review.
Zakaria Y; Yahya N; Kissani N
Cureus; 2024 Mar; 16(3):e57289. PubMed ID: 38690505
[TBL] [Abstract][Full Text] [Related]
52. Rapidly progressive cognitive impairment resulting in heavy psychosocial burden in a patient with Fabry disease undergoing hemodialysis: a case report.
Ohsawa I; Onuki A; Oka F; Matsuoka Y; Makita Y; Kobayashi T; Kanaguchi Y; Nakamura Y; Suzuki Y; Goto Y; Gotoh H
BMC Nephrol; 2024 Jun; 25(1):188. PubMed ID: 38831308
[TBL] [Abstract][Full Text] [Related]
53. Oxidative stress and its role in Fabry disease.
Cacciapuoti M; Bertoldi G; Caputo I; Driussi G; Carraro G; Calò LA
J Nephrol; 2024 Jun; ():. PubMed ID: 38878155
[TBL] [Abstract][Full Text] [Related]
54. Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease.
De Marco O; Gambardella J; Bianco A; Fiordelisi A; Cerasuolo FA; Buonaiuto A; Avvisato R; Capuano I; Amicone M; Di Risi T; Riccio E; Spinelli L; Pisani A; Iaccarino G; Sorriento D
Front Cardiovasc Med; 2024; 11():1396996. PubMed ID: 38756750
[TBL] [Abstract][Full Text] [Related]
55. Pathologic findings of Fabry nephropathy: the pivotal role of kidney biopsy.
Shin JH; Kim SH
Kidney Res Clin Pract; 2021 Dec; 40(4):508-511. PubMed ID: 34922427
[No Abstract] [Full Text] [Related]
56. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
Waldek S; Feriozzi S
BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
[TBL] [Abstract][Full Text] [Related]
57. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
Putko BN; Wen K; Thompson RB; Mullen J; Shanks M; Yogasundaram H; Sergi C; Oudit GY
Heart Fail Rev; 2015 Mar; 20(2):179-91. PubMed ID: 25030479
[TBL] [Abstract][Full Text] [Related]
58. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
[TBL] [Abstract][Full Text] [Related]
59. Fabry disease.
Schiffmann R
Handb Clin Neurol; 2015; 132():231-48. PubMed ID: 26564084
[TBL] [Abstract][Full Text] [Related]
60. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases.
Merscher S; Fornoni A
Front Endocrinol (Lausanne); 2014; 5():127. PubMed ID: 25126087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
